Aromasin was first released on the U.S. market in 2000 after shortly gaining FDA approval a few months prior in 1999. The primary purpose of use as with most AI’s would be to combat breast cancer in post-menopausal women. Shortly after, the AI would begin to gain a lot of popularity among anabolic steroid users for its ability to protect against estrogenic related side effects. This action is very similar to the older and more popular AI’s in Arimidex (Anastrozole) and Femara (Letrozole). It would also gain a fair amount of popularity in Post Cycle Therapy (PCT) plans among steroid users. It was not the first AI to gain such popularity but would prove to be a little more advantageous for this purpose than most AI’s.